# Fitlife Brands, Inc.: Form 10-Q for the period ended Jun 30, 2017

- Company: [Fitlife Brands, Inc.](/companies/ftlf.md) (CIK 1374328)
- Form: 10-Q
- Filed: 2017-08-21
- Accepted by EDGAR: Aug 21, 2017, 16:53 ET
- Period: 2017-06-30
- Accession: 0001654954-17-007797
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1374328/000165495417007797/ftlf10q_june302017.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1374328/000165495417007797/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-04-01 to 2017-06-30 | $5.0m | us-gaap:Revenues |
| Revenue | 6 months, 2017-01-01 to 2017-06-30 | $10.6m | us-gaap:Revenues |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $1.5m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $3.4m | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | −$517.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | −$823.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $29.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $55.7k | us-gaap:InterestExpense |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | −$551.6k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | −$884.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 10,470,158 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 10,455,814 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2017-01-01 to 2017-06-30 | $423.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $10.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-06-30 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $7.9m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $15.1m | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $5.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $5.4m | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $89.1k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-06-30 | $554.7k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-06-30 | $9.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 14,635 characters.

### Forward-Looking Statements

Management’s Discussion and Analysis contains various “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-Q, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to “anticipates”, “believes”, “plans”, “expects”, “future” and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company’s business, including but not limited to, reliance on key customers and competition in its markets, market demand, product performance, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. The Company adopted at management’s discretion, the most conservative recognition of revenue based on the most astringent guidelines of the SEC. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled “*Risk Factors”* in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

### Overview

FitLife Brands, Inc. (the “*Company”*) is a national provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition ProductsTM (“*NDS”) (*www.ndsnutrition.com), PMDTM (www.pmdsports.com), SirenLabsTM (www.sirenlabs.com), CoreActiveTM (www.coreactivenutrition.com), and Metis NutritionTM (www.metisnutrition.com) (together, “*NDS Products”*). With the consummation of the merger with iSatori, Inc. (“*iSatori”*) on September 30, 2015, which became effective on October 1, 2015, described below (the “*Merger”*), the Company added several brands to its product portfolio, including iSatori (www.isatori.com), BioGenetic Laboratories, and Energize (together, “*iSatori Products”).* The NDS Products are distributed principally through franchised General Nutrition Centers, Inc. (“*GNC”*) stores located both domestically and internationally, and, with the addition of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 25,000 retail locations, which include specialty, mass, and online.

The Company was incorporated in the State of Nevada on July 26, 2005. In October 2008, the Company acquired the assets of NDS Nutritional Products, Inc., a Nebraska corporation, and moved those assets into its wholly owned subsidiary NDS Nutrition Products, Inc., a Florida corporation (“*NDS”*). The Company’s NDS Products are sold through NDS and the iSatori Products are sold through iSatori, Inc., a Delaware corporation and a wholly owned subsidiary of the Company.

FitLife Brands is headquartered in Omaha, Nebraska and maintains an office in Golden, Colorado, which it acquired in connection with the Merger. For more information on the Company, please go to http://www.fitlifebrands.com. The Company’s common stock currently trades under the symbol FTLF on the OTC:PINK market.

### Results of Operations

### Comparison of Three and Six Months Ended June 30, 2017 to the Three and Six Months Ended June 30, 2016

*Net Sales.* Revenue for the three months ended June 30, 2017 decreased 42.0% to $5,022,338 as compared to $8,662,760 for the three months ended June 30, 2016. Revenue for the six months ended June 30, 2016 decreased 34.8% to $10,611,693 as compared to $16,274,989 for the six months ended June 30, 2016. Revenue for the six months ended June 30, 2017 included a one-time non-recurring adjustment of $700,000 related to a margin support credit memorandum entered into between the Company and GNC in April 2017.

Revenue for the three months ended June 30, 2017 for the Company’s NDS Nutrition division decreased 40.0% to $3,594,507 as compared to $5,993,166 for the three months ended June 30, 2016. The decrease in total revenue attributable to NDS products is principally attributable to the impact of convention revenue during the second quarter in 2016 and the Company’s election not to attend the convention in 2017 as well as efforts of the Company’s largest distribution partner to reduce average existing inventory levels to fulfill product demand in the short term, which resulted in an unprecedented divergence of wholesale purchases compared to product movement at retail. Revenue attributable to the Company’s iSatori operating division was $1,427,831 during the quarter ended June 30, 2017 compared to $2,669,595 for the three months ended June 30, 2016. The decrease in total revenue attributable to iSatori products in the three months ended June 30, 2017 compared to the comparable period last year is attributable to several factors, principally to fewer new product introductions during the period as compared to the prior year and the restructuring and reorganization at iSatori’s largest third-party distributor. The impact of both are expected to stabilize in the coming quarters and management anticipates that it will continue to benefit from new product introductions going forward as a key element of its strategic growth plan for both iSatori and NDS.

*Cost of Goods Sold.* Cost of goods sold for the three months ended June 30, 2017 decreased to $3,499,120 as compared to $4,851,166 for the three months ended June 30, 2016. The decrease during the three-month period is principally attributable to lower sales in the period. Cost of goods sold for the six months ended June 30, 2017 decreased to $7,167,910 as compared to $9,115,857 for the six months ended June 30, 2016. The decrease during the six-month period is principally attributable to lower sales in the period. Notwithstanding the decrease, cost of goods sold was negatively impacted during the second quarter ended June 30, 2017 by an unusually large amount of inventory write-offs totaling approximately $376,000, of which $276,000 related to the write off of all remaining inventory with picamilion.

*General and Administrative Expense.* General and administrative expense for the three months ended June 30, 2017 decreased to $1,009,934 as compared to $1,356,464 for the three months ended June 30, 2016. The decrease in general and administrative expense for the three months ended June 30, 2017 is principally attributable to ongoing cost reduction initiatives as well as the continued integration efforts at the iSatori division which resulted in a lower headcount. General and administrative expense for the six months ended June 30, 2017 decreased to $2,170,003 as compared to $2,745,671 for the six months ended June 30, 2016. The decrease in general and administrative expense for the six months ended June 30, 2017 is similarly attributable to ongoing cost reduction initiatives and cost savings resulting from the integration of iSatori.

*Selling and Marketing Expense.* Selling and marketing expense for the three months ended June 30, 2017 decreased to $913,371 as compared to $1,111,129 for the three months ended June 30, 2016. Selling and marketing expense for the six months ended June 30, 2017 decreased to $1,860,758 as compared to $2,026,687 for the six months ended June 30, 2016. The decrease in selling and marketing expense for the three and six and month periods ended June 30, 2017 is principally the result of budgetary controls and efficiencies gained through the acquisition of iSatori.

*Depreciation and Amortization.* Depreciation and amortization for the three months ended June 30, 2017 decreased to $117,312 as compared to $125,995 for the three months ended June 30, 2016. Depreciation and amortization for the six months ended June 30, 2017 decreased to $236,650 as compared to $250,751 for the six months ended June 30, 2016.

*Net Income/(Loss).* We generated a net loss of $(551,559) for the three-month period ended June 30, 2017 as compared to a net income of $1,079,036 for the three months ended June 30, 2016. The decrease in net income for the three-month period ended June 30, 2017 compared to the comparable period last year is principally attributable to lower sales volumes due to a variety of factors discussed above and write-off activity. We generated a net loss of $(884,449) for the six-month period ended June 30, 2017 as compared to a net income of $1,893,190 for the six months ended June 30, 2016, which was principally attributable to a one-time non-recurring adjustment of $700,000 related to a margin support credit memorandum entered into between the Company and GNC in April 2017, lower sales volumes, increased write-off activity and the decision to not participate in 2017 annual franchise convention.

### Liquidity and Capital Resources

The Company has historically financed its operations primarily through equity and debt financings, and more recently, cash flow from operations. The Company has also provided for its cash needs by issuing common stock, options and warrants for certain operating costs, including consulting and professional fees. The anticipated cash derived from operations and existing cash resources are expected to provide for the Company’s liquidity for the next 12 months.

*Cash Provided by Operations.* Our cash provided by operating activities for the six months ended June 30, 2017 was $418,100, as compared to cash provided by operating activities of $176,610 for the six months ended June 30, 2016. The increase is primarily attributable to variations in certain working capital accounts consistent with normal business practices and outcomes. Net working capital decreased to $2,660,220 as of the quarter ended June 30, 2017 compared to $5,059,096 as of June 30, 2016.

*Cash Used in Investing Activities.* Cash used in investing activities for the six months ended June 30, 2017 was $(4,888) as compared to $(19,592) used in investing activities for the six months ended June 30, 2016.

*Cash Provided by (Used in) Financing Activities.* Our cash used in financing activities for the six months ended June 30, 2017 was $(275,879), as compared to cash provided by financing activities of $250,548 during the six months ended June 30, 2016. The primary difference was that we drew down $520,000 during the six months ended June 30, 2016 from our existing line of credit with U.S. Bank and made no draw downs on the line of credit during the six months ended June 30, 2017. The line of credit matured on June 15, 2017; however, U.S. Bank has agreed to extend the maturity date of the line of credit for an additional 60 days to August 15, 2017. The line of credit is secured by substantially the assets of the Company. During the 60-day period in which U.S. Bank has extended the maturity date of the line of credit, U.S. Bank is conducting an audit of the Company’s assets securing the line of credit. We expect to pay back all amounts borrowed under the line of credit, as well as any outstanding principal under the Company’s existing term loan with U.S. Bank as soon as practicable.

### Goodwill and Indefinite-Lived Intangible Assets

The Company had goodwill and indefinite-lived intangible assets with a carrying value of $4,422,448 and $1,875,495, respectively, as of the quarter ended June 30, 2017. In accordance with ASC Topic 350 – Goodwill and Other Intangible Assets, in lieu of amortizing such amounts the Company assesses the carrying value of such intangible assets for impairment on a periodic basis and records an impairment charge if the carrying value of such intangible assets exceeds the estimated fair value of the reporting unit, which in this case is the Company. The Company performed its annual goodwill impairment test as of December 31, 2016, which did not indicate the existence of an impairment at that time. While the fiscal year-to-date financial performance has not met our expectations, and the enterprise value of the Company based on current price of the stock the Company may fluctuate at or near the recorded levels of goodwill and indefinite-lived intangible assets, Management does not consider these results to be a triggering event requiring the performance of an interim goodwill impairment test. The Company will continue to monitor its operating results for indicators of impairment and perform additional tests as necessary. The Company's fiscal 2017 annual impairment test will be performed as of December 31, 2017, which could result in an impairment charge to goodwill depending on the Company’s finalized forecast for fiscal 2018 and other market conditions.

### WHERE YOU CAN FIND MORE INFORMATION

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

## Market risk

As filed, 1,411 characters.

Our business is currently conducted principally in the United States. As a result, our financial results are not affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets. We do not engage in hedging transactions to reduce our exposure to changes in currency exchange rates, although as the geographical scope of our business broadens, we may do so in the future.

Our exposure to risk for changes in interest rates relates primarily to our investments in short-term financial instruments. Investments in both fixed rate and floating rate interest earning instruments carry some interest rate risk. The fair value of fixed rate securities may fall due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income may fall short of expectations due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.

We do not hold any derivative instruments and do not engage in any hedging activities.

## Controls and procedures

As filed, 3,982 characters.

(a) *Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“*COSO”*). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the COSO to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was effective as of June 30, 2017. This Quarterly Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our internal control over financial reporting was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

(b) *Changes in Internal Controls Over Financial Reporting*

There have been no changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended June 30, 2017. There have not been any significant changes in the Company's critical accounting policies identified since the Company filed its Annual Report on Form 10-K as of December 31, 2016.

### PART II

### OTHER INFORMATION

## Risk factors

As filed, 213 characters.

There are no risk factors identified by the Company in addition to the risk factors previously disclosed in Part I, Item 1A, “*Risk Factors”* in our Annual Report on Form 10-K for the year ended December 31, 2016.

Filed Aug 21, 2017.
Source: SEC EDGAR, the filing index for accession 0001654954-17-007797. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.
